alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 28 studies by Whitmer RA (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Midlife cardiovascular risk factors and risk of dementia in late life

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Neurology 2005-01-01

The presence of multiple cardiovascular risk factors at midlife substantially increases risk of late-life dementia in a dose dependent manner. 5 key findings →

Design: cohort study Participants: 8,845 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA 2025-08-01

Among older adults at risk of cognitive decline and dementia, a structured, higher-intensity intervention had a statistically significant greater benefit on global cognition compared with an unstructured, self-guided intervention. 5 key findings →

Participants: 1,056 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 70 out of 100. JAMA network open 2022-04-01

These findings suggest that this blood biomarker test could allow for distinguishing individuals with brain amyloid-positive PET findings from individuals with amyloid-negative PET findings and serve as an aid for Alzheimer disease diagnosis. 4 key findings →

Design: cohort study Participants: 249 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Inequalities in dementia incidence between six racial and ethnic groups over 14 years

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Alzheimer's & Dementia 2016-03

This large study followed over 274,000 members of a single California health system for 14 years and found striking differences in dementia rates by race and ethnicity. 5 key findings →

Design: cohort Participants: 274,283 Evidence: high

Full summary, score breakdown and related studies → Original source

Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study

✓ Peer-reviewed alzhub usefulness score 68 out of 100. BMJ 2005-06-09

Tracking over 10,000 people for 27 years, this landmark study found that being obese in midlife (in your 40s) nearly doubled the risk of developing dementia decades later, and being overweight also raised the risk, independent of whether someone later developed diabetes or heart disease. 4 key findings →

Design: cohort Participants: 10,276 Evidence: high

Full summary, score breakdown and related studies → Original source

Midlife risk score for the prediction of dementia four decades later

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-09-10

A combination of modifiable vascular risk factors in midlife is highly predictive of the likelihood of dementia decades later. 1 key finding →

Design: cohort study Participants: 2,767 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

✓ Peer-reviewed alzhub usefulness score 65 out of 100. BMJ (Clinical research ed.) 2010-01-12

Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population. 5 key findings →

Design: prospective cohort Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association Between Birth in a High Stroke Mortality State, Race, and Risk of Dementia

✓ Peer-reviewed alzhub usefulness score 63 out of 100. JAMA neurology 2017-09-01

Overall, birth in an HSMS was associated with a 28% higher risk of dementia (adjusted hazard ratio [aHR], 1.28; 95% CI, 1.13-1.46) adjusted for age, sex, and race. 5 key findings →

Design: cohort study Participants: 7,423 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Inequalities in dementia incidence between six racial and ethnic groups over 14 years

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2016-02-11

Dementia rates varied over 60% between groups, providing a comprehensive benchmark for the NAPA goal of reducing disparities. 2 key findings →

Participants: 18,778 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Archives of general psychiatry 2012-05-01

Depressive symptoms in midlife or in late life are associated with an increased risk of developing dementia. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Survival after dementia diagnosis in five racial/ethnic groups

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017-02-05

Survival after dementia diagnosis differs by race/ethnicity, with shortest survival among whites and longest among Asian Americans. 3 key findings →

Participants: 23,032 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Timing of hormone therapy and dementia: the critical window theory revisited

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Annals of neurology 2010-11-12

Although previous research has shown that initiation of postmenopausal estrogen hormone therapy (HT) in late life increases risk of dementia, animal studies and some observational studies have suggested that midlife use of HT may be beneficial; however, this has not been rigorously investigated in large population-based studies. 4 key findings →

Participants: 1,524 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

APOE-ε4 carriership and dementia risk over 10 years among Asian American and White older adults

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & Dementia 2026-07

Despite differences in prevalence of APOE-ε4, its association with dementia risk was similar across Chinese, Japanese, Filipino, and non-Latino White participants. 2 key findings →

Design: cohort Participants: 46,325 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Archives of internal medicine 2010-10-25

In this large cohort, heavy smoking in midlife was associated with a greater than 100% increase in risk of dementia, AD, and VaD more than 2 decades later. 5 key findings →

Participants: 5,367 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Racial/ethnic differences in dementia risk among older type 2 diabetic patients: the diabetes and aging study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Diabetes care 2013-11-22

Among type 2 diabetic patients followed for 10 years, African Americans and Native Americans had a 40-60% greater risk of dementia compared with Asians, and risk was intermediate for non-Hispanic whites and Latinos. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive dysfunction in diabetes: how to implement emerging guidelines

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Diabetologia 2019-08-16

Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognised as an important comorbidity and complication of diabetes that affects an individual's well-being and diabetes management, and is associated with diabetes treatment-related complications. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed